within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG11_Anifrolumab;

model Anifrolumab
  extends Pharmacolibrary.Drugs.ATC.L.L04AG11;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L04AG11</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Anifrolumab is a fully human monoclonal antibody that targets the type I interferon receptor subunit 1 (IFNAR1), blocking activity of type I interferons implicated in the pathogenesis of systemic lupus erythematosus (SLE). It is approved for the treatment of moderate to severe SLE in adults who are receiving standard therapy.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics reported in adult SLE patients (including males and females) after intravenous administration.</p><h4>References</h4><ol><li><p>Tummala, R, et al., &amp; Santiago, L (2018). Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers. <i>Lupus science &amp; medicine</i> 5(1) e000252–None. DOI:<a href=\"https://doi.org/10.1136/lupus-2017-000252\">10.1136/lupus-2017-000252</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29644080/\">https://pubmed.ncbi.nlm.nih.gov/29644080</a></p></li><li><p>Tang, W, et al., &amp; MacDonald, A (2023). Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. <i>Clinical pharmacokinetics</i> 62(5) 655–671. DOI:<a href=\"https://doi.org/10.1007/s40262-023-01238-2\">10.1007/s40262-023-01238-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37148484/\">https://pubmed.ncbi.nlm.nih.gov/37148484</a></p></li><li><p>Almquist, J, et al., &amp; Chia, YL (2022). Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus. <i>Journal of clinical pharmacology</i> 62(9) 1106–1120. DOI:<a href=\"https://doi.org/10.1002/jcph.2055\">10.1002/jcph.2055</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35383948/\">https://pubmed.ncbi.nlm.nih.gov/35383948</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Anifrolumab;
